Previous drugs developed to impede tyrosine kinase activity for cancer treatment have had limited success, as one of the major challenges is the presence or development of resistance to treatment with long-term use, such as acquired resistance to epidermal growth factor receptor (EGFR) inhibitors [21]. This evidence concerns the gene EGFR and cancer.